A
2.65
-0.06 (-2.22%)
| Previous Close | 2.71 |
| Open | 2.73 |
| Volume | 93,920 |
| Avg. Volume (3M) | 787,047 |
| Market Cap | 291,909,024 |
| Price / Earnings (Forward) | 8.47 |
| Price / Sales | 12.53 |
| Price / Book | 9.22 |
| 52 Weeks Range | |
| Earnings Date | 11 May 2026 |
| Profit Margin | -139.74% |
| Operating Margin (TTM) | -1,216.52% |
| Diluted EPS (TTM) | -1.26 |
| Quarterly Revenue Growth (YOY) | -76.90% |
| Total Debt/Equity (MRQ) | 43.39% |
| Current Ratio (MRQ) | 3.34 |
| Operating Cash Flow (TTM) | -229.34 M |
| Levered Free Cash Flow (TTM) | -92.86 M |
| Return on Assets (TTM) | -17.22% |
| Return on Equity (TTM) | -90.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Alector, Inc. | Bullish | Bullish |
AIStockmoo Score
2.0
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Average | 2.00 |
|
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.61% |
| % Held by Institutions | 80.74% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Foresite Capital Management Iv, Llc | 31 Dec 2025 | 3,887,200 |
| Merck & Co., Inc. | 31 Dec 2025 | 3,545,719 |
| 52 Weeks Range | ||
| Median | 6.00 (126.84%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 10 Mar 2026 | 6.00 (126.84%) | Buy | 2.38 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |